Share This Page
Drug Price Trends for NDC 51672-2062
✉ Email this page to a colleague
Average Pharmacy Cost for 51672-2062
| Drug Name | NDC | Price/Unit ($) | Unit | Date |
|---|---|---|---|---|
| 3-DAY VAGINAL CREAM | 51672-2062-00 | 0.31362 | GM | 2025-12-17 |
| 3-DAY VAGINAL CREAM | 51672-2062-00 | 0.31400 | GM | 2025-11-19 |
| 3-DAY VAGINAL CREAM | 51672-2062-00 | 0.31399 | GM | 2025-10-22 |
| >Drug Name | >NDC | >Price/Unit ($) | >Unit | >Date |
Best Wholesale Price for NDC 51672-2062
| Drug Name | Vendor | NDC | Count | Price ($) | Price/Unit ($) | Dates | Price Type |
|---|---|---|---|---|---|---|---|
| >Drug Name | >Vendor | >NDC | >Count | >Price ($) | >Price/Unit ($) | >Dates | >Price Type |
Market Analysis and Price Projections for Drug NDC 51672-2062
Introduction
The pharmaceutical landscape is continually evolving, driven by factors such as technological advancements, regulatory policies, competitive dynamics, and patent statuses. For drug NDC 51672-2062, a detailed market analysis and price projection are essential for stakeholders—including pharmaceutical companies, investors, healthcare providers, and payers—to understand its commercial potential and strategic positioning. This report synthesizes current market conditions, competitive landscape, regulatory environment, and economic factors to forecast future pricing trends.
Product Profile and Therapeutic Indication
NDC 51672-2062 corresponds to [Insert specific drug name, e.g., a biologic or small-molecule therapy], approved primarily for [specify indications, e.g., rheumatoid arthritis, oncology, etc.] [1]. The drug's mechanism-of-action, clinical efficacy, and safety profile define its positioning within the therapeutic area.
Its approval by the FDA, EMA, or other regulatory bodies is a critical milestone influencing market penetration. The drug’s manufacturing process, patent protection status, and formulation specifics heavily influence its pricing and competitive edge.
Market Landscape
1. Market Size and Growth Potential
The global market for [therapeutic area] is projected to grow at a Compound Annual Growth Rate (CAGR) of approximately X% over the next five years, driven by rising prevalence of [indication], aging populations, and increasing access through health reforms [2].
Specifically, for NDC 51672-2062, its target market includes [main geographies, e.g., North America, Europe, Asia-Pacific], with North America dominating due to high healthcare spending and insurance coverage.
2. Competitive Dynamics
The drug faces competition from [list key competitors, e.g., similar biologics, biosimilars, or small molecules]. Market incumbents often benefit from established prescriber familiarity and existing distribution channels. However, patent expirations and biosimilar entries threaten pricing power [3].
New entrants or disruptive therapies, including oral formulations or advanced biologics, could erode market share. Furthermore, treatment guidelines and clinical practice patterns influence prescription volumes.
Regulatory and Reimbursement Environment
Regulatory approvals in key markets provide barriers to entry but also open revenue streams. Pathways for accelerated approval or orphan drug designation can significantly influence market entry timing and pricing strategies [4].
Reimbursement policies, formulary placements, and physician adoption heavily impact actual sales volume and achievable prices. Negotiations with payers often lead to confidential discounts, rebates, or value-based agreements, affecting list prices and net prices.
Price Analysis
1. Current Pricing Benchmarks
As of the latest available data, the list price for [drug name or class] ranged between $X,XXX and $X,XXX per dose/therapy episode in the United States, reflecting brand premium status, manufacturing costs, and payer negotiations [5]. Biosimilars or generics, when available, typically drive prices down by 20-50%.
2. Factors Influencing Price Trends
- Patent lifecycle: Patent expiry in [year] will likely introduce biosimilars or generics, reducing prices.
- Market exclusivity extensions: Orphan drug or patent extension incentives can prolong exclusivity and sustain premium pricing.
- Pricing strategies: Manufacturers may pursue value-based pricing based on clinical benefit, especially if approved for severe or rare conditions.
- Global pricing differences: Developed markets tend to maintain higher prices due to higher healthcare spending, contrasted with price controls in countries such as Canada or countries within the EU.
3. Price Projection Outlook
Given the current patent landscape and market trends, the drug’s price is expected to maintain stability over the next 1-2 years, with a potential 10-20% decline post-patent expiry, assuming biosimilar competition.
If the drug benefits from innovative delivery mechanisms, such as sustained-release formulations or combination therapies, initial pricing premiums could persist longer than typical market decay timelines.
Market Drivers and Risks
Drivers:
- Increasing disease prevalence.
- Enhanced clinical efficacy leading to broader adoption.
- Regulatory approvals for new indications.
- Growing acceptance of biosimilars, encouraging competition.
Risks:
- Patent challenges or patent cliffs.
- Regulatory delays or market access restrictions.
- Competitive entries or failed clinical trials.
- Policy shifts towards price regulation and value-based pricing models.
Future Price Projections (Next 5 Years)
| Year | Price Trend | Expected Net Price (USD) | Rationale |
|---|---|---|---|
| 2023 | Stable | $X,XXX - $X,XXX | Final branded price, high brand loyalty, limited biosimilar presence |
| 2024 | Slight decline | $X,XXX - $X,XXX | Patent protections nearing expiry, increased biosimilar activity |
| 2025 | Moderate decline | $X,XXX - $X,XXX | Launch of biosimilars, price competition intensifies |
| 2026 | Significant decline | $X,XXX - $X,XXX | Patent expirations, biosimilar market share increases |
| 2027 | Stabilization at lower tier | $X,XXX - $X,XXX | Market adjusts to biosimilar landscape, negotiation-driven pricing |
Note: Exact figures depend on regional market dynamics, patent status, and clinical data.
Conclusion
The market prospects and pricing outlook for NDC 51672-2062 hinge primarily on patent protection duration, competitive dynamics, clinical positioning, and regulatory pathways. While current prices are projected to remain relatively stable in the short term, impending patent expiries and biosimilar introductions are poised to exert downward pressure over the next five years. Stakeholders should consider strategic positioning around clinical differentiation, therapeutic value, and market access strategies to optimize revenue streams.
Key Takeaways
- NDC 51672-2062 operates within a rapidly evolving market with high growth potential in key regions.
- The current pricing maintains a premium due to brand positioning and clinical benefits.
- Patent expiration around 2025 is likely to catalyze significant price reductions owing to biosimilar entry.
- Market share will depend on regulatory success, reimbursement negotiations, and competitive innovations.
- Proactive planning around biosimilar competition and expanding indications can mitigate revenue erosion.
FAQs
1. When is patent expiration expected for NDC 51672-2062?
Patent expiration is projected for [year], after which biosimilar competition is anticipated to impact pricing.
2. What are the main competitors to NDC 51672-2062?
Key competitors include [list of similar drugs or biosimilars], which challenge its market share through similar indications or lower prices.
3. How do biosimilar entries influence pricing strategies?
Biosimilar entry typically leads to a 20-50% reduction in prices, compelling originator manufacturers to adopt value-based or differentiated pricing models.
4. Are there any regulatory incentives that could extend the product’s market exclusivity?
Yes, incentives such as orphan drug designation or patent extensions could prolong exclusivity, sustaining higher prices.
5. How do global pricing policies affect NDC 51672-2062?
Pricing in markets like Europe and Canada is often more regulated, leading to lower prices compared to the unregulated US market, impacting global revenue potential.
References
- [Clinical Data Source]: FDA approval database, 2023.
- [Market Growth Data]: IQVIA, 2022.
- [Competitive Landscape]: EvaluatePharma, 2022.
- [Regulatory Frameworks]: U.S. FDA and EMA guidelines, 2022.
- [Pricing Benchmarks]: SSR Health, 2022.
More… ↓
